Advanced search
Publication Cover
Clinical Toxicology Volume 53, 2015 - Issue 8
Submit an article Journal homepage
639
Views
10
CrossRef citations to date
0
Altmetric
Poison Centre

Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally

Anselm WongVictorian Poisons Information Centre and Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia;Monash Health Clinical Toxicology Service and School Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, AustraliaCorrespondence[email protected]
,
Dawson MacleodVictorian Poisons Information Centre and Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia
,
Jeff RobinsonVictorian Poisons Information Centre and Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia
,
Zeff KoutsogiannisVictorian Poisons Information Centre and Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia
,
Andis GraudinsMonash Health Clinical Toxicology Service and School Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia
&
Shaun L. GreeneVictorian Poisons Information Centre and Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia
Pages 815-818 | Received 23 Mar 2015, Accepted 04 Jun 2015, Published online: 25 Jun 2015

References

  • Poelaert J, Koopman-Klein G, Dioh A, Louis F, Gorissen M, Logé D, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015; 37:784–792.
  • Electronic Medicines Compendium UK website. https://www.medicines.org.uk/emc/medicine/22908. Last accessed 24th February 2015.
  • US Food and Drug Administration Website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406407.htm. Last accessed 24th February 2015.
  • Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Bell D. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012; 50: 360–367.
  • Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. MJA. 2011. 195: 280–284.
  • Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005. 22:612–616.
  • Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014; 139:9–17.
  • Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin®. N Engl J Med. 2012; 367:187–189.
  • Kang JH, Lee GW, Shin SH, Bruera E. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J Pain Symptom Manage. 2013. 46:e15–17.
  • Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingested of crushed embeda (morphine extended release with sequestered naltrexone): case report and focused review of the literature. J Opioid Manag. 2013. 6: 300–303.
  • Fischer A, Jönsson M, Hjelmström P. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm. 2015. 41:79–84.
  • Therapeutic Goods Australia database of adverse events notifications. https://www.tga.gov.au/database-adverse-event-notifications-daen. Last accessed 9 February 2015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.